date:May 15, 2014
ceived from 5LINX for NIAGEN and PURENERGY. Based on visibility of sales activity from both our existing customers and our business development pipeline, we anticipate steady growth in our ingredient segment to continue for the foreseeable future.
Media outlets are starting to highlight peer reviewed research studies from esteemed institutions on the potential health benefits of NAD+ precursors, such as nicotinamide riboside (NR). We expect new research will continue to be published which wil